A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
Clinical trial NCT05338957 · UNKNOWN
Trial details
- NCT number
- NCT05338957
- Sponsor
- Shanghai Miracogen Inc.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-05
- Primary completion
- 2024-06-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.